Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cytopia Vows Fight To Keep Avexa From Progen In All-Australia Battle

This article was originally published in PharmAsia News

Executive Summary

Australia's Cytopia is urging shareholders of Avexa to vote for its firm to merge with the biotech in late March to stave off any new hostile takeovers. Cytopia CEO Andrew Macdonald said he is not through yet in his battle to keep Progen Pharmaceuticals from trying to obtain control of Avexa, and urged shareholders to ignore Progen's promise it is ready to begin commercializing Avexa's PI-88 drug and already is in talks with Taiwain regulators. Cytopia said in an interview the Progen assertion was just a smokescreen. (Click here for more

You may also be interested in...



Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.

In A Bizarre Move, Trump Orders GM To Make Ventilators – Even Though The Auto Giant Already Is

President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.

Start-Up Spotlight: Iraq War Veteran Deploys ‘Bone Paint’ To Combat Traumatic Injuries

Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.

UsernamePublicRestriction

Register

SC071039

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel